Achieve Life Sciences, Inc. (ACHV) stock
ACHVNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31Also trades as QUIT
$6.72+0.34 (+5.33%)
Close on Nov 6, 2026Market cap $708.81MP/E –Yield –
Achieve Life Sciences total assets
Total assets on the balance sheet at the end of each period.
Achieve Life Sciences's total assets was $206.42M at Sep 30, 2026. For fiscal 2025 it was $41.79M, up 8.2% from the year before. Over ten years it grew -3.3% a year on average. The highest annual figure on record is $89.92M in fiscal 2010.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $41.79M | +8.2% |
| FY2024 | Dec 31, 2024 | $38.63M | +99.4% |
| FY2023 | Dec 31, 2023 | $19.37M | -35.4% |
| FY2022 | Dec 31, 2022 | $29.97M | -36.9% |
| FY2021 | Dec 31, 2021 | $47.52M | +17.9% |
| FY2020 | Dec 31, 2020 | $40.30M | +91.2% |
| FY2019 | Dec 31, 2019 | $21.08M | +10.4% |
| FY2018 | Dec 31, 2018 | $19.08M | +92.9% |
| FY2017 | Dec 31, 2017 | $9.89M | +159.8% |
| FY2016 | Dec 31, 2016 | $3.81M | -93.5% |
| FY2015 | Dec 31, 2015 | $58.21M | +3.4% |
| FY2014 | Dec 31, 2014 | $56.29M | +1.1% |
| FY2013 | Dec 31, 2013 | $55.69M | -32.1% |
| FY2012 | Dec 31, 2012 | $82.02M | +20.6% |
| FY2011 | Dec 31, 2011 | $68.02M | -24.4% |
| FY2010 | Dec 31, 2010 | $89.92M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $206.42M | +296.7% |
| Q2 FY2026 | Jun 30, 2026 | $190.44M | +223.1% |
| Q1 FY2026 | Mar 31, 2026 | $33.11M | +21.0% |
| Q4 FY2025 | Dec 31, 2025 | $41.79M | +8.2% |
| Q3 FY2025 | Sep 30, 2025 | $52.04M | +8.6% |
| Q2 FY2025 | Jun 30, 2025 | $58.94M | -9.0% |
| Q1 FY2025 | Mar 31, 2025 | $27.36M | -60.9% |
| Q4 FY2024 | Dec 31, 2024 | $38.63M | +99.4% |
| Q3 FY2024 | Sep 30, 2024 | $47.92M | +96.9% |
| Q2 FY2024 | Jun 30, 2024 | $64.79M | +124.1% |
| Q1 FY2024 | Mar 31, 2024 | $70.03M | +236.7% |
| Q4 FY2023 | Dec 31, 2023 | $19.37M | -35.4% |
| Q3 FY2023 | Sep 30, 2023 | $24.34M | +2.6% |
| Q2 FY2023 | Jun 30, 2023 | $28.92M | -14.9% |
| Q1 FY2023 | Mar 31, 2023 | $20.80M | -48.8% |
| Q4 FY2022 | Dec 31, 2022 | $29.97M | -36.9% |
| Q3 FY2022 | Sep 30, 2022 | $23.72M | -37.2% |
| Q2 FY2022 | Jun 30, 2022 | $33.99M | -25.4% |
| Q1 FY2022 | Mar 31, 2022 | $40.61M | +20.7% |
| Q4 FY2021 | Dec 31, 2021 | $47.52M | +17.9% |
| Q3 FY2021 | Sep 30, 2021 | $37.80M | +36.9% |
| Q2 FY2021 | Jun 30, 2021 | $45.57M | +176.9% |
| Q1 FY2021 | Mar 31, 2021 | $33.66M | +102.2% |
| Q4 FY2020 | Dec 31, 2020 | $40.30M | +91.2% |
| Q3 FY2020 | Sep 30, 2020 | $27.62M | +140.3% |
| Q2 FY2020 | Jun 30, 2020 | $16.46M | +11.5% |
| Q1 FY2020 | Mar 31, 2020 | $16.65M | +14.8% |
| Q4 FY2019 | Dec 31, 2019 | $21.08M | +10.4% |
| Q3 FY2019 | Sep 30, 2019 | $11.49M | -33.0% |
| Q2 FY2019 | Jun 30, 2019 | $14.76M | -23.2% |
| Q1 FY2019 | Mar 31, 2019 | $14.50M | +71.4% |
| Q4 FY2018 | Dec 31, 2018 | $19.08M | +92.9% |
| Q3 FY2018 | Sep 30, 2018 | $17.14M | +31.6% |
| Q2 FY2018 | Jun 30, 2018 | $19.22M | +29.2% |
| Q1 FY2018 | Mar 31, 2018 | $8.46M | -52.7% |
| Q4 FY2017 | Dec 31, 2017 | $9.89M | +159.8% |
| Q3 FY2017 | Sep 30, 2017 | $13.03M | – |
| Q2 FY2017 | Jun 30, 2017 | $14.88M | – |
| Q1 FY2017 | Mar 31, 2017 | $17.90M | – |
| Q4 FY2016 | Dec 31, 2016 | $3.81M | – |
See a number that looks wrong?